Mixed Wall Street Performance: Healthcare Stocks Surge as GE Faces Supply Chain Woes

Key Facts

1Merck & Co (MRK) stock rose 3.24% driven by optimism over its late-stage oncology and immunology pipeline.

2AbbVie (ABBV) stock climbed 3.32% following positive clinical trial outcomes for Skyrizi and Rinvoq.

3General Electric (GE) stock declined 4.08% due to concerns over GE Aerospace engine supply chain bottlenecks.

Amid notable sectoral shifts in the U.S. market, healthcare and industrial stocks exhibited divergent performances reflecting investor focus on pharmaceutical innovation versus operational hurdles. Merck (MRK) shares rose 3.24% driven by optimism over its oncology and immunology pipeline, while AbbVie (ABBV) climbed 3.32% following positive clinical trial outcomes. Conversely, General Electric (GE) shares declined 4.08% due to mounting concerns over engine supply chain bottlenecks within its aerospace division.

This divergence highlights a broader rotation into defensive sectors with stable dividends, as clinical successes for Skyrizi and Rinvoq bolstered investor confidence in AbbVie's long-term growth. Per market data, GE's decline comes as the global aerospace sector grapples with rising operational costs; previous industry reports have suggested that engine delivery delays could weigh on profit margins through the second half of the year. Compared to industrial peers, the healthcare sector has demonstrated superior resilience during recent market volatility.

As of the close on July 15, 2026, MRK stood at $123.61, ABBV at $244.11, and GE at $360.35. Investors should monitor further updates regarding aerospace supply chains and the lingering impact of the Fed's Monetary Policy Report released on July 10, which may influence financing costs for large-cap industrial firms in the coming weeks.